Corrigendum: Telmisartan prevents alveolar bone loss by decreasing the expression of osteoclasts markers in hypertensive rats with periodontal disease (2021)
- Authors:
- USP affiliated authors: LARA, VANESSA SOARES - FOB ; SANTOS, CARLOS FERREIRA DOS - FOB
- Unidade: FOB
- DOI: 10.3389/fphar.2020.635927
- Subjects: RECEPTORES DE ANGIOTENSINA; RATOS; DOENÇAS PERIODONTAIS; HIPERTENSÃO; MICROTOMOGRAFIA; OSTEOCLASTO; OSSO E OSSOS
- Language: Inglês
- Imprenta:
- Source:
- Título: Frontiers in Pharmacology
- ISSN: 1663-9812
- Volume/Número/Paginação/Ano: v. 11, art. 635927, Feb. 2021
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
BRITO, Victor Gustavo Balera et al. Corrigendum: Telmisartan prevents alveolar bone loss by decreasing the expression of osteoclasts markers in hypertensive rats with periodontal disease. Frontiers in Pharmacology, v. 11, 2021Tradução . . Disponível em: https://doi.org/10.3389/fphar.2020.635927. Acesso em: 04 out. 2024. -
APA
Brito, V. G. B., Patrocinio, M. S., Sousa, M. C. L. de, Barreto, A. E. A., Frasnelli, S. C. T., Lara, V. S., et al. (2021). Corrigendum: Telmisartan prevents alveolar bone loss by decreasing the expression of osteoclasts markers in hypertensive rats with periodontal disease. Frontiers in Pharmacology, 11. doi:10.3389/fphar.2020.635927 -
NLM
Brito VGB, Patrocinio MS, Sousa MCL de, Barreto AEA, Frasnelli SCT, Lara VS, Santos CF dos, Oliveira SHP de. Corrigendum: Telmisartan prevents alveolar bone loss by decreasing the expression of osteoclasts markers in hypertensive rats with periodontal disease [Internet]. Frontiers in Pharmacology. 2021 ; 11[citado 2024 out. 04 ] Available from: https://doi.org/10.3389/fphar.2020.635927 -
Vancouver
Brito VGB, Patrocinio MS, Sousa MCL de, Barreto AEA, Frasnelli SCT, Lara VS, Santos CF dos, Oliveira SHP de. Corrigendum: Telmisartan prevents alveolar bone loss by decreasing the expression of osteoclasts markers in hypertensive rats with periodontal disease [Internet]. Frontiers in Pharmacology. 2021 ; 11[citado 2024 out. 04 ] Available from: https://doi.org/10.3389/fphar.2020.635927 - Role of mast cell and RAS in mice periodontal tissue
- Mast cells supernatant inhibit bone formation markers gene expression in SHR osteoblasts
- Mast cells contribute to alveolar bone loss in Spontaneously Hypertensive Rats with periodontal disease regulating cytokines production
- Telmisartan prevents alveolar bone loss by decreasing the expression of osteoclasts markers in hypertensive rats with periodontal disease
- Aliskiren attenuates the inflammatory response and wound healing process in diabetic mice with periodontal disease
- Telmisartan impairs the in vitro osteogenic differentiation of mesenchymal stromal cells from spontaneously hypertensive male rats
- Mast cells increase gene expression of osteoclastogenic markers in SHR
- Morphologic evaluation and expression of matrix metalloproteinases-2 and 9 and nitric oxide during experimental periodontal disease in rat
- Losartan plays a fungistatic and fungicidal activity against candida albicans biofilms: drug repurposing for localized candidosis
- Evaluation of SAP expression in experimental model of denture stomatitis
Informações sobre o DOI: 10.3389/fphar.2020.635927 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas